Search company, investor...

Ocularis Pharma

ocularispharma.com

Stage

Other Investors | Alive

About Ocularis Pharma

Night Vision Complaints, which range from patient dissatisfaction to complete impairment due to glare, halos, starbursts, ghosting patterns, poor contrast and poor depth perception in dim light, have been recognized for many years, but have only received significant attention in the past decade, as the advent of intraocular lens implants and refractive surgery has produced significant numbers of patients who experience acute and chronic NVCs post-operatively. There is no medication on the market today indicated for the treatment of Night Vision Complaints. To address the problem of NVCs due to light scatter, Ocularis has patented the use of an entire class of molecules that have been demonstrated to inhibit pupil dilation in dim light. The lead product, Nyxol Eye Drops, has been shown to be safe and effective in reducing pupil size in a Phase I clinical trial. Furthermore, Ocularis has successfully tested the drug in a Phase I/II clinical study demonstrating statistically and clinically significant improvement in low contrast visual acuity in dim light. A Phase II clinical study in patients with moderate to severe night vision complaints is underway. Management expects to develop Nyxol Eye Drops within four years with a broad indication that will permit its use in the widest possible range of patient groups.

Headquarters Location

2436 S 6th Avenue

North Riverside, Illinois, 60546,

United States

Missing: Ocularis Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ocularis Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ocularis Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ocularis Pharma is included in 1 Expert Collection, including Pharma Supply Chain.

P

Pharma Supply Chain

1,258 items

Ocularis Pharma Patents

Ocularis Pharma has filed 9 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/25/2017

5/11/2021

Ophthalmology, Vision, Beta blockers, Diseases of the eye and adnexa, Stereoscopy

Grant

Application Date

9/25/2017

Grant Date

5/11/2021

Title

Related Topics

Ophthalmology, Vision, Beta blockers, Diseases of the eye and adnexa, Stereoscopy

Status

Grant

Ocularis Pharma Frequently Asked Questions (FAQ)

  • Where is Ocularis Pharma's headquarters?

    Ocularis Pharma's headquarters is located at 2436 S 6th Avenue, North Riverside.

  • What is Ocularis Pharma's latest funding round?

    Ocularis Pharma's latest funding round is Other Investors.

  • Who are the investors of Ocularis Pharma?

    Investors of Ocularis Pharma include Capital Midwest Fund.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.